Skip to content

Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30)

Prospective Trials on Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With D2 Extra-regional Lymph Node Dissection for Locally Advanced Gastric Cancer (FUGES-30)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06945718
Enrollment
760
Registered
2025-04-25
Start date
2025-05-01
Completion date
2030-05-01
Last updated
2025-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer, Surgery

Keywords

Gastric Cancer, Laparoscopic Gastrectomy, Indocyanine Green Tracer

Brief summary

Taking patients with locally advanced gastric adenocarcinoma (cT2-4a, N-/+, M0) as the research subjects, to evaluate whether the clinical efficacy of laparoscopic beyond D2 regional lymph node dissection for gastric cancer with indocyanine green tracer is better or not.

Interventions

PROCEDUREbeyond D2 regional lymph node dissection

dissect the lymph nodes outside the extent of D2 LN region.

Sponsors

Fujian Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

Age from 18 to 75 years Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy cT2-4a, N-/+, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual, 8th Edition No distant metastasis, no direct invasion of pancreas, spleen or other adjacent organs in the preoperative examinations Performance status of 0 or 1 on the ECOG (Eastern Cooperative Oncology Group) scale ASA (American Society of Anesthesiology) class I to III Written informed consent

Exclusion criteria

Women during pregnancy or breast-feeding Severe mental disorder History of previous upper abdominal surgery (except for laparoscopic cholecystectomy) History of previous gastric surgery (including ESD/EMR for gastric cancer) Enlarged or bulky regional lymph node (diameter over 3cm) supported by preoperative imaging including enlarged or bulky lymph nodes in D3 region. Other malignant disease within the past 5 years History of unstable angina or myocardial infarction within past six months History of cerebrovascular accident within past six months History of continuous systematic administration of corticosteroids within one month Requirement for simultaneous surgery for other disease Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer FEV1 (forced expiratory volume in one second)\<50% of predicted values Diffuse invasive gastric cancer Tumors preoperatively confirmed to involve the squamocolumnar junction or duodenum History of an iodine allergy Patients who declined laparoscopic surgery

Design outcomes

Primary

MeasureTime frameDescription
3-year disease free survival rate3 yearsDisease-free survival is calculated from the day of surgery to the day of recurrence or death

Secondary

MeasureTime frameDescription
Noncompliance rate of lymph node dissection30 daysThe LN dissection rate was determined by the number of patients in whom a LN station was harvested divided by the total number of patients who required retrieval at the corresponding LN station. Within the scope of D2 dissection, LN noncompliance was defined as the absence of LNs that should have been resected from \> 1 LN station.
Relationship between fluorescent lymph nodes in group A and total number of lymph nodes in group A30 daysRelationship between the number of fluorescent lymph nodes in group A and total number of lymph nodes in group A
Relationship between fluorescent lymph nodes in Group A and positive lymph nodes in Group A (positive rate)30 daysThe number of positive lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group A (True positive rate).
Relationship between fluorescent lymph nodes in Group A and negative lymph nodes in Group A (false positive rate)30 daysThe number of negative lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group A (false positive rate).
Relationship between non-fluorescent lymph nodes in Group A and negative lymph nodes in group A (negative rate)30 daysThe number of negative lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in group A (True negative rate).
Relationship between nonfluorescent lymph nodes in Group A and positive lymph nodes in Group A (false negative rate)30 daysThe number of positive lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in Group A (false negative rate).
Relationship between fluorescent lymph nodes in group B and total number of lymph nodes in group B30 daysRelationship between the number of fluorescent lymph nodes in group B and total number of lymph nodes in group B
Relationship between fluorescent lymph nodes in Group B and positive lymph nodes in Group B (positive rate)30 daysThe number of positive lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group B (True positive rate).
Relationship between fluorescent lymph nodes in Group B and negative lymph nodes in Group B (false positive rate)30 daysThe number of negative lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group A (false positive rate).
Relationship between non-fluorescent lymph nodes in Group B and negative lymph nodes in group B (negative rate)30 daysThe number of negative lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in group B (True negative rate).
Total number of retrieved lymph nodes30 daysTotal number of retrieved lymph nodes
Number of metastatic lymph nodes30 daysNumber of metastatic lymph nodes
Metastasis rate of lymph nodes30 daysMetastasis rate of lymph nodes
Postoperative complications30 daysPostoperative complications were evaluated within 30 days following surgery. These postoperative complications include gastrointestinal-related complications, incision-related complications, respiratory complications, cardiovascular and cerebrovascular complications, urinary system complications, infection complications, embolism complications, and other complications. The grading of postoperative complications adopts the Clavien-Dindo classification.
Mortality rates30 daysPatient died during hospitalization.
3-year overall survival rate3 years3-year overall survival rate
3-year recurrence pattern3 years3-year recurrence pattern
Postoperative recovery course30 daysTime to first flatus after surgery, time to first ambulation after surgery, time to first liquid diet after surgery, time to first semi-liquid diet after surgery, length of hospital stay after surgery.
The incidence of intraoperative complications30 daysIntraoperative complications were defined as bleeding due to named vessel injury, injury to visceral organs, mechanical factor-related problems, cardiopulmonary dysfunction due to hypercapnia, and other complications
Inflammatory and immune response7 daysthe values of hemoglobin, prealbumin, albumin, C-reactive protein, and white blood cell count from peripheral blood before the operation and on postoperative day 1, 3, 5 are recorded.
Relationship between nonfluorescent lymph nodes in Group B and positive lymph nodes in Group B (false negative rate)30 daysThe number of positive lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in Group B (false negative rate).

Countries

China

Contacts

Primary ContactMi Lin, phD
silihuala@qq.com13459152658
Backup ContactHua-Long Zheng, phD
291167038@qq.com18359190587

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026